SCHEMBL3880063

SCHEMBL3880063

CC(C)(C)OC(=O)NC(=O)N1CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.46
HPGD P15428 1/20 0.45
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX15 P16050 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
EPHX1 P07099 1/20 0.40
MAPT P10636 1/20 0.39
PREP P48147 1/20 0.38
EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669491 0.98 CTSK (0.45) CTSKHPGDHTTSMN1; SMN2ALOX15
SCHEMBL945981 0.94 MAPT (0.43) CTSKHPGDHTTSMN1; SMN2ALOX15
SCHEMBL4738498 0.82 EPHX2 (0.38) CTSKHPGDSMN1; SMN2CA1CA2
SCHEMBL8191256 0.77 HPGD (0.39) CTSKHPGDCA1CA2GAA
SCHEMBL8191259 0.77 HPGD (0.39) CTSKHPGDCA1CA2GAA
SCHEMBL30487923 0.75 HPGD (0.50) CTSKHPGDHTTSMN1; SMN2CA1
SCHEMBL28856990 0.75 HPGD (0.50) CTSKHPGDHTTSMN1; SMN2CA1
SCHEMBL19853105 0.75 HPGD (0.43) CTSKHPGDSMN1; SMN2CA1CA2
SCHEMBL27760998 0.75 EPHX1 (0.38) CTSKHPGDHTTSMN1; SMN2GAA
SCHEMBL7040760 0.75 CTSK (0.38) CTSKHPGDSMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250265-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D VANDERBILT UNIVERSITY 2025-08-07 US disclosed
WO-2023201014-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF N-ACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D VANDERBILT UNIVERSITY (US) 2023-10-19 WO disclosed
CN-108473426-B Cyclic amine derivative and medical use thereof 东丽株式会社 2021-09-07 CN disclosed
CN-111566098-A Cyclic amine derivatives and pharmaceutical use thereof 东丽株式会社 2020-08-21 CN disclosed
CN-110913859-A Therapeutic or prophylactic agent for round alopecia 东丽株式会社 2020-03-24 CN disclosed
US-7553831-B2 Beta-secretase inhibitors; inhibiting cleavage of amyloid precursor protein (APP); hydroxy-functional disubstituted amines such as 6-(([[(2S,3S)-4-(3,5-difluorophenyl)-3-((3-[(dipropylamino)carbonyl]benzoyl)amino)-2-hydroxybutyl](ethyl)amino]carbonyl)amino)hexanoic acid ELAN PHARMACEUTICALS, INC. (US) 2009-06-30 US disclosed
EP-1919907-A2 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 EP disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
US-20050203096-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS, INC. 2005-09-15 US disclosed
US-6846813-B2 For inhibiting beta-secretase enzyme activity and A beta peptide production, inhibition of beta-secretase enzyme activity halts or reduces production of A beta from APP and reduces or eliminates the formation of beta-amyloid deposits PHARMACIA & UPJOHN COMPANY (US) 2005-01-25 US disclosed
US-20020143177-A1 Compounds to treat alzheimer's disease PHARMACIA & UPJOHN COMPANY 2002-10-03 US disclosed
WO-2002002518-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO disclosed
WO-2002002520-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250265-A1 BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D PLD1, PLD2, NAPEPLD CTSK 229/4885HPGD 596/4885HTT 1598/4885
US-20020143177-A1 Compounds to treat alzheimer's disease PSEN2, PSEN1, CHAT CTSK 1388/4885HPGD 713/4885HTT 62/4885
US-20050203096-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT CTSK 1338/4885HPGD 493/4885HTT 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.